NCT04856917 - A Study to Evaluate the Efficacy and Safety of Imsidolimab (ANB019) in the Treatment of Participants With Acne Vulgaris | Biotech Hunter

Enrollment

123

Participants

Timeline

Start Date

May 15, 2021

Primary Completion Date

February 1, 2022

Study Completion Date

March 29, 2022

Conditions

Acne Vulgaris

Interventions

DRUG

Imsidolimab

Humanized Monoclonal Antibody

BIOLOGICAL

Placebo

Trial Locations (15)

Site 10-113, Sweetwater

Site 10-108, Tampa

Site 10-107, Tampa

Site 10-105, Murfreesboro

Site 10-104, Detroit

Site 10-109, New Orleans

Site 10-112, New Orleans

Site 10-114, Hot Springs

Site 10-102, College Station

Site 10-101, San Antonio

Site 10-103, Austin

Site 10-106, Sherman Oaks

Site 10-111, Fountain Valley

Site 10-110, Portsmouth

Site 10-115, Waterloo